9.01

3.22% -0.30

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Financials Discussions Forecast

Kura Oncology Inc stock is traded at $9.01, with a volume of 1.17M. It is down -3.22% in the last 24 hours and down -17.87% over the past month. Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Previous Close:

$9.31

Open:

$9.465

24h Volume:

1.17M

Relative Volume:

0.70

Market Cap:

$799.86M

Revenue:

$71.64M

Net Income/Loss:

$-294.57M

P/E Ratio:

-2.6912

EPS:

-3.348

Net Cash Flow:

$-84.46M

1W Performance:

-13.28%

1M Performance:

-17.87%

6M Performance:

+10.96%

1Y Performance:

+48.93%

1-Day Range:

$8.87

$9.465

1-Week Range:

$8.82

$10.77

52-Week Range:

$5.45

$12.49

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

(858) 500-8800

Address

4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA

Employee

260

Twitter

@kuraoncology

Next Earnings Date

2026-08-06

Latest SEC Filings

KURA's Discussions on Twitter

Compare KURA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KURA Kura Oncology Inc	9.01	901.06M	71.64M	-294.57M	-84.46M	-3.348
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Lake Street	Buy
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-14-24	Downgrade	Stifel	Buy → Hold
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

Jul 28, 2026

Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma - Bitget

Jul 27, 2026

H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jul 27, 2026

Kura Oncology Reports 50% Response Rate in RCC Combination Study - Yahoo Finance

Jul 27, 2026

Kura Oncology Market Sentiment - Benzinga España

Jul 27, 2026

Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial - Bitget

Jul 27, 2026

KURA Shows Promising Results in Phase 1a Kidney Cancer Trial - GuruFocus

Jul 27, 2026

Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma - Quiver Quantitative

Jul 27, 2026

Kura's Drug Combo Shows 13-Month Median Without Progression - Stock Titan

Jul 27, 2026

Jul 25, 2026